UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment ...Middle East

Orismilast Phase 2b results in atopic dermatitis (AD) presented today as a late-breaking oral presentation at the European Academy of Dermatology and Venerology (EADV) Congress 2024 Orismilast demonstrated clear treatment effect with statistical significance for all dose arms on the...

Hence then, the article about union therapeutics announce results from the adesos phase 2b study in atopic dermatitis confirming the potential of orismilast as a first in class safe and efficacious oral treatment was published today ( Wednesday 25/09/2024 - 06:41 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( UNION therapeutics announce results from the ADESOS Phase 2b study in atopic dermatitis confirming the potential of orismilast as a first-in-class safe and efficacious oral treatment )

Also on site :

• Musk mulling mega-mergers – Bloomberg
• Can Cell Phones Stop ICE?
• Kurdish-led SDF agrees integration with Syrian government forces